Evidence map›Paper›PMID 24653654›Full record

ArticleClinical Medicine Insights. Oncology2014

Impact of Gender in Renal Cell Carcinoma: The Relationship of FABP7 and BRN2 Expression with Overall Survival.

Cheng Tan, Tatsuya Takayama, Naohisa Takaoka, Hiromi Fujita, Miki Miyazaki, Takayuki Sugiyama, Seiichiro Ozono

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cheng TanDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Tatsuya TakayamaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Naohisa TakaokaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hiromi FujitaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Miki MiyazakiDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Takayuki SugiyamaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Seiichiro OzonoDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Hamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the relationship between gender differences in fatty acid-binding protein7 (FABP7) and BRN2 (POU class 3 homeobox 2) expression in renal cell carcinoma (RCC) and the prognosis of patients with RCC. MATERIALS AND

methodsimmunohistochemical (IHC) staining as well as reverse transcription-polymerase chain reaction (RT-PCR) was performed in renal tissues from 103 patients (83 men, mean age = 63.6 years old; 20 women, mean age = 63.1 years old) underwent radical nephrectomy from January 1, 2001 through December 31, 2010. The probability of overall patient survival was estimated using the Kaplan-Meier method.

resultsFABP7 mRNA expression was more frequent in men (P = 0.07) while BRN2 protein expression was significantly more frequent in women (P = 0.029). In particular, FABP7 was expressed in 100% of G1 renal cell carcinoma both in mRNA and protein levels. In women, FABP7 (-) and BRN2 (+) groups had a worse prognosis both in mRNA level (P = 0.038) and protein level (P = 0.058). BRN2 was expressed 100% of papillary RCC both in mRNA and protein levels.

conclusionsOur results demonstrated that gender was a key factor in FABP7 and BRN2 expression in RCC, and the combination with FABP7 and BRN2 stratified by gender could be a new potential prognostic factor in patients with RCC.

Indexed as

BRN2FABP7genderoverall survivalrenal cell carcinoma

Identifiers

PMID24653654
PMCPMC3937181
OpenAlexW1894781685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.